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INTRODUCTION
Mouse mammary tumor is a common form of cancer used
for experimental purposes.
chemotherapy.

It is relatively resistant to

This investigation is designed to test the

effect of heparin, a naturally occurring anticoagulant, on
tumor growth using a genetically uniform laboratory animal.
The

c 3H/HeJ

Mouse

Dr. Clarence C. Little was among the first to recognize the usefulness of genetic uniformity in reducing the
variables associated with experimental work (1).
•

He pointed

out that genetically similar populations allow investigators
to check their own observations and allow other researchers
to verify the results (1) .

Use of the

c 3H

strain of mouse in

the present project eliminates histocompatibility problems .
The

c 3 HjHeJ

is a strain of the

mouse, which is agouti in color (2)

c 3H

mouse d e veloped by careful inbreeding .

The J indicates that it is a subline of
developed by Strong (2,3).

The

c 3H

c 3 HjSt,

a strain

mouse was, in turn,

developed from the C family and was initially introduced
around the year of 1918 (4- 1 2).
Between the y e ars of 1918 and 1 920 (2,3,4-13), Strong

1

2
crossed a female Bagg albino mouse with a DAB* male to produce the inbred strain c H which was developed separately from
3
other strains (2, 4-12).
to Andervant.

In 1930, Strong gave the

c 3H

About 1938 -1941, Andervant passed the

mouse

c 3 HjHeJ

mouse at F35 to Heston (the F35 refers to the inbreeding of
the 35th generation of brothers and sisters).

In 1947-1948

Heston gave the F48, which is the 48th breeding of brothers
and sisters, to Jackson Laboratory and in 1980 this laboratory purchased the Fl50 generation from Jackson Laboratory
for this research.
The

c3 H

strain has more than 10 major sublines (14).

Most of these sublines have good reproductive capacity (14)
and exhibit a very high incidence of spontaneous mouse
mammary tumor (2,3,13-16).
Strong and Heston have indicated that the incidence
of the spontaneous developing mouse mammary tumor in the

c 3HjHeJ

mouse is highest in the breeding female (65%), lower

in the virgin female (28%) and lowest in the male (2 - 3,17).
The

c 3 HjHeJ

subline exhibits a uniformity in a variety

of characteristics useful for experimental biology (1,2,13).
Certain characteristics, such as coat color and rd (retinal
degeneration gene), are highly uniform (2,4-11).

Minor fac-

tors, such as the life span, susceptibility to constitutional
disease, and other physiological characteristics are not

*Little's mice were used in color experiments and
represent one of the oldest inbred strain (since 1907).

3

absolutely uniform because their expressio n is a function
of both heredity and environment (2,13,18) .
ge netic c haracteristics of the

c3H

Th e uniform

mo us e are of gr eat im-

portance in certain aspects of cancer.

These findings

make the unfostered sublines appropriate models for research
into mammary tumor biol ogy (13, 18-21).
Th e

c 3 HjHeJ

subline exhibits a poor immun e r es ponse

to endotoxic lipopolysaccharide ( 14); this is thou ght to be
due to a B lymphocyte de f i c it .
normality of the

c 3 HjHeJ

One exp lanation fo r this ab-

immune system would be an a ltered

h e matopoeitic system s in ce both low r e d and whit e cel ls
counts are observed in the live animal (4-ll).
An understanding of mammary tumor morphology requires
st udy' of normal and abnorma l mammary tissue.

In the fol l ow-

i ng section, these topi cs will b e discussed:

(i) the no rmal

mouse ma mmary tissue, including gross morp holo gy a nd microscop ic anatomy, a nd (ii) tumorous mouse mammary tissue, ineluding pathogenesis and facto r s influe n c ing tumorogenesis .
No rmal Mouse Mammary Ti ss u e
A

c 3 HjHeJ

'

mouse h as five pairs of mammary g l a nds ,

t hr ee thoracic and two inguino-abdominal (22).

Dissect ion of

these g l a nd s s hows that t h e healthy tissue is opaque, whit e
in co l o r and pulpy in texture ( 2,

2:3 , · 24).

Histologically, normal mouse mammary ti ss u e undergoes
various c han ges durin g pub e rty, pregnancy, lactation, a nd
involution (20,25-28).

Th e inactive mammary gla nd (Figur e 1)

~

Figure 1.

C3HjHeJ mouse inactive mammary tissue (10 X).

Note the low ratio

of glandular tissue (elements) to adipose tissue.

5

is hypoplastic with very few glandular elements (25).

Preg-

nancy (Figure 2) induces remarkable growth of tubules and
secretory alveoli (29).

The alveoli are empty _of sec reti o ns

early in pregnancy (29, 30).
The most remarkable change occurs durin g lactation
(Figure 3), when the alveoli increase in size .

At this

time, most of the alveolar lumens contain lar ge volumes of
lipid and protein secretions (31).

This situation continues

until the involutional stage (Figure 4) .

At th a t time, con-

traction of the glandular tissue takes place and t he alveoli
become smaller although they remain irregular (25,26).
Mous e Mammary Tumor
On April 24, 1946, a spontaneous ma mma r y a d e nocarcinoma was detected in a nine-month-old female mouse of the
s train

c 3H.

(32) .

Since that time, ma mmary adeno carcinoma tissue has

Th e tumor was c h a r acterized and transplanted

been transplanted s u ccessfully by subcutaneous, intramuscular, intraocul ar, intrahepati c a nd intraperitoneal inoculati on .
Mouse ma mma r y tumor i s of two hi sto l ogical types:
o n e consisti n g of s mall, uniform aci n i s up ported by minimal
st r o ma; the other, a so lid mass of tumor cells arranged i n
nodul es surrounded b y co nnective tissue (23,24,33).
la tter ( Fi gur e 5) h as been ob served more of t e n in the

The

c 3H

mouse (23,24 .,34) .
Altho u gh t h e transplantability characteristic of

0')

Figure 2 .

C3HjHeJ mouse p r egnant mammary tissue (10 X) .

Note the increase
in relative numbers of mammary acini to adipose tissue . Also
observable is the presence of lipid and protein secretions in ducts .

....:]

Figure 3 .

C3HjHeJ mouse lactati ng

man~ary tissue (10 X) .
A striking increase
in glandular elements with relative reduction in connective/adipose
tissue can be observed.

(X)

Figure 4 .

C3H/HeJ mouse involuting mammary tissue (10 X) . No te a reduction
of glandular elements; appearance is similar to the inacti v e state .

CD

Figure 5 .

C3HjHeJ mouse spontaneous mammary tissue (10 X) . A solid mass of
glandular like tissue with scant connective tissue is shown here .
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the mouse mammary tumor tissue is by far the most important
indicator for its malignant nature (35), other characteristics such as a naplasia and rapid growth with demise (death)
of the animal are also strong evidence for its malignant
nature (15, 18).
Mouse mammary tumor virus has been known to be
oncogenic since 1918.
tumor virus (MMTV),

An RNA oncogenic virus, mouse mamma ry
is transmitted from an infected mother

to the offspring by nursi ng (13, 15, 16).
The mouse mammary tumor virus can be identified in
the milk (15, 16).

A spontaneous mouse mammary tumor will

develop in a genetically susceptible animal unde r the influence of this virus and probably other e nviornmental factors

·c 15).

Several factors influence tumorogenesis ( 36)

includin g:
(i)

Virus:

Other viruses in addition to mouse

mammary tumor virus are known to cause mouse
mammary tumor ( 15, 36, 37) .
(ii)

Genotype:

The susceptibility of mi ce to

develop spontaneous mo us e mammary tumor is
depende nt o n her e dity (15 , 16).

In some r e -

sistant strains such as C57BL, I, 020 and
C57BL/l0, mouse mammary tumor virus will fail
to devel op a high mammary cancer incidence (15).
(iii)

Hormonal Environment:

Virus -induced mammary

tumors are essentially hormone-independent

11
(16); they can grow not only in normal females but also in castrated females or in
males (16).

However, in susceptible (virus-

carrying) strains of mice, such as the

c 3 HjHeJ

mouse, hormonal stimulation results in much
higher incidence of mouse mammary adenocarcinoma
(16).

This hormonal factor has been supported

by many experiments showing that ovarian extracts, estrogen or estrogen-progestogen
combinations do, in fact, stimulate oncogenesis
(38); others such as glucocorticoids, dexamethasone, prolactin, and insulin also seem
to play some role

(39~45) · .

Tumor Transplantation
Tumor transplantation is a technique wher e by a viable
tumor can be transplanted from a donor animal to a syngeneic
host.

The value of this technique resides in the fact that

tumor viability can be maintained continuously as cells are
passaged from one animal to another.

This technique is of

great value in cancer and/or immunological research (46).
The history of tumor transplantation goes back more
than a century when many investigators thought that the transplantable tumors might be better tools for cancer andjor immunological r e search than spontaneous or induced tumors.

1876, M.A. Novinsky (1841-1914), known as the father of
tumor transplantation, successfully transplanted, possibly

In
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for the first time, a spontaneous malignant tumor.

He used

a dog because at that time small laboratory animals were not
widely used (47).
Novinsky drew several conclusions:

first, he noted

that it was possible to perform implantation of a tumor;
second, that inoculation success depended on several factors:

(i) size of the initial incision of the skin,

(ii)

the size of the tumor inoculum, and (iii) the quantity of
viable cells present in the transplant.

He also suggested

that tumor cells should be considered as infecting agents
to healthy tissue, and that species identity between the
donor and the host should be considered during inoculation
( 47).
The credit for successful tumor transplantation in
laboratory animals has been misguidedly awarded t o Hanau ,
who in November 28, 1888 successfully inoculated two rats
with an epidermoid rat carcinoma.

Hanau hims e lf refers to

Novinsky's work on tumor transplantation in dogs (47,48).
During the period of 1889-1952, Kanematsu Su giura
with three other authors, as well as four independent investigators, reported that rat and mouse tumors as well as vene r eal
sarcoma in the dog could be successfully transplanted (47).
At the present time, there are more than 100 known
transplantable tumors of the mouse, rat, hamst er, guinea pig,
rabbit, dog, a nd c hi cke n.
Even minor factors (di scussed later) play an important
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role in the success of tumor transplantation.

Successful

transplantation of a solid tumor requires the following instruments:

stainless steel dissecting scissors, forceps

with medium point, curved dissecting forceps, dissecting
knife and trocars (46).

The trocar is a special stainless

steel 13-gauge instrument made especially for tumor transplantation .

The wide bore of the trocar is well known to

cause less damage to the tumor cells.
In solid tumor transplantation, it has been re co mmended that the non-necrotic, nonhemorrhagic tumor mass be
cut into small cubes prior to transplantation since the
response in the host and tumor survival will depend on the
size of the tumor mass (46).
Tumor transplant growth is facilitated if transplanted into a histocompatible host or an immunosuppresse d
host or a n a nimal such as the nude mouse.

Otherwise, the

normal immune system, in particul ar T lymphoc ytes, may rej ect it (46, 47) .
Becaus e of the ease of transplantation, the most
suitable site is into axillary subcutaneous tissue.

It

has been noted that tumor take and growth are best in young,
healthy, vigorous mic e and r ats, r egardless of sex although
sexes should be separated to prevent pregnancy (46).
Successf ul mous e mammary tumor impl e mentati o n can be
detected at the implementation site within a week (46, 47) .
In the ma mmary adenocarcinoma transplant, rapid growth is
generally o b ser ved , although this i s depend ent o n several
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factors such as inoculation size and site.

Animal death

occurs within weeks (46).
Other factors can contribute to the failure of transplanted tumor cells to establish themselves.

Th e se include:

(i) inoculation of stationary or receding tumors, (ii) inoculation of stored frozen tumors, (iii) spontaneous regression
of transplantable tumors, and (iv) resistance to inoculation
(46,47).
Dvorak Model
In 1979, Dvorak et al., postulated that solid tumors
have the ability to stimulate the formation of a protective
fibrin cocoon around the tumor (49).

Dvorak suggested that

this "fibrin cocoon might enable the tumor cells to develop
without challenge from the host's immune surveillance system
or provide some other survival advantages (49-54).
Prior to cocoon formation,

tumor cells release a

vascular permeability factor (VPF) at an early stage after
transplantation.

This factor increases vascular permeability

locally in the region of the tumor, allowing blood constituents, including fibrinogen, to escape into the tissue bordering the tumor.

The VPF is not histamine mediated (49).

In addition to the release of the VPF factor , tumor
cells release a procoagulation factor (PCF) which in turn
triggers the blood clotting cascade leading to fibrin formation in the form of a cocoon .

This has been observed to

occur within hours aft e r transplant (49).
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In order to allow for future tumor growth, Dvorak
postulated production of a third factor called plasminogen
activator factor (PAF).

PAF activates plasmin to stimulate

fibrinolysis and as the tumor grows, the cocoon is then
able to be reshaped.
A migration inhibitory factor (MIF), which has the
capacity to inhibit migration of macrophages to the tumor
zone, is postulated by Dvorak as an additional (fourth) factor promoting tumor growth (49).
The central core of the Dvorak hypothesis is the
fibrin cocoon.

He has suggested that the cocoon is advan-

tageous for tumor growth since it may protect neoplastic
cells from the host immune surveillance system.

He also

noted that the fibrin cocoon is apparently associated with
the development of new blood vessels that penetrate the
tumor (49).

The presence of the fibrin cocoon has been

confirmed by immunofluorescence as well as by electron
microscopy.
Special Project
Other workers have noted a relationship between
tumor growth and coagulation.

In 1958, Wood demonstrated

that tumor cells have to become engulfed in a fibrin
clot as a prerequisite for metastasis (53).

This was fol-

lowed in 1960 by the work of Hiramoto et al., who demonstrated the presence of e xtravascular fibrin deposits within
tumors (54).

In 1971 it became clear (Folkman) that a tumor

fibrin matrix supporting a capillary network was essential

16
for tumor survival (55).

Lastly, several investigators

between the years of 1973-1981 (Elias et al . ; Brown;
Zacharski et al.; Poggi et al. ), have shown that anticoagulants will protect the host against metastasis
(56-60).
The present research project was designed to exami n e
the effect of a naturally occurring anticoagul a nt (heparin)
on tumor growth in an experimental animal .

Th e hypothesis

was to test the relationship between heparin and Dvorak's
hypothesis using transplanted mammary tumors and the

c 3 HjHeJ

female mouse, ' known for its high incidence of spontaneous
mammary tumor.

As a solid tumor, mammay tumor tissue is

ideal for such investigation since solid tumors can be retrieved and weighed easily.
Heparin, since its discovery in 1916, has been used
world wide clinically for its anticoagulation properties
(61-80).

The mechanism of action involves its highly

charged acidic properties.

Heparin action sites in the

coagulation cascade are indicated in Figure 6 (66, 79).

Al-

though it has seve ral sites of action, its dominant effect
is the inhibition of thrombin formation.
Brambel proposed that heparin, with its cofactor
antithrombin III, inactivates factor V by forming a "heparin
cofactor-factor V heparin complex" (80).

This results in

a deficiency of the prothrombin activator complex which is
normally composed of factor Xa (activated factor X) and

17.
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Factor V plus phospholipids and calcium .

The net result of

this inhibition is a decrease in thrombin production (66,
69, 79).

The "heparin cofactor-factor V heparin complex"

undoubtedly occurs because heparin is a strongly charged
(negative) molecule (69).
Another observation has been made by Soulier and
Lewis, who noted that the presence of a heparin cofactor,
a plasma alpha-globulin called antithrombin III is essential
(79,81,82) for its antithrombotic activity.
In the body, heparin is stored naturally in mast
cells bound to histamine and 10-24 units %, (0.1 - 0 .24 mg/
100 ml) can be found circulating in blood plasma, where it
pres umably acts as a "natural" anticoagulant ( man, horse)
( 69).

In addition to its anticoagulant activity, heparin

has some "antiinflammatory" properties.

Dragstedt, in 1942 ,

observed that histamin e reacts with heparin to form a nonreactive (histamine-heparinate) complex, ther eby inhibiting
the release of histamine during an antigen-antibody reaction (83).

This antiinflammatory action is not related to

anticoagulant activity (84) .
Heparin is also known to have some antilipemic and
anticomplementary activity (6'7, 84) .

MATERIALS AND METHODS
Tumor Transplantation
To obtain material for implantation, a female donor

C3HjHeJ mouse with a spontaneous mammary tumor (Figure 7)
was sacrificed using diethyl ether.

The dorsal surface of

the dead animal was swabbed with 70% ethanol, an incision
made, skin retracted and pinned back, and the tumor carefully dissected from the surrounding tissue.

When separated

from surrounding tissue, the tumor appeared as an opaque,
yellowish-white mass .

After several washings using sterile

Ringer's solution (46), the tumor was dissec te d into c ub es
measuring approximately 2 x 2 x 2 mm (see Fi gure 8) with an
average weight of 0 . 0179 g (obs e rved range= 0 . 0115
0.0244 g) .
Fifty-four (27 control),

c 3HjHeJ

females weigh ing

20-26 g were used as the host animals (85,8G) .
plants

o~

6.3 x 10

8

Tumor im-

the above dimension and consisting of approximately
cells were used .

Animals were exposed to dieth yl

e ther for approximately 50 seconds until mot o r coordination
was lost .

With the animal prone, a 3 mm incis ion was made

on the lowe r back after bathin g th e area with 70% ethanol
(Figure 9).

A 13-gauge needle, containing tumor tissue, was

introduced subcutaneously into the tissue via the s k i n incision
19
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1:\:)

....

Figure 8 .

Diced specimens of mammary tumors as prepared for implantation.

22
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and directed toward the implantation site midway between the
left shoulder and left hip in the axillary line (Figure 10) .
Tumor implantation was completed by introducing a plunger
into the barrel of the needle.

A clockwise followed by a

counter-clockwise rotation of the plunger insured complete
evacuation of the tumor.
carefully removed.
skin incision.

The trocar and its plunger were

No sutures were required to repair the

Tumor samples were randomly distributed by

weight within the test groups.
Drug Treatment
Twenty-four hours prior to tumor transplantation ,
the 54 experimental animals were divided randomly into two
groups:

27 as control and 27 which received intraperito-

neally 4 mgjkg heparin sodium (128 Ufmg) at that time.
is twice the normal anticoagulation dose.

This

The experimental

group continued to receive heparin sodium (4 mgjkg) every
12 hours .
Whole Blood Clotting Time Measurement
Using a tapered glass pipette (approximately 10 em
in length), approximately 2.0 ml of blood were drawn from
the periorbital venous plexus of the ey e .

This sample was

then placed in a well on a thin glass plate and housed in
a water bath at 370 C.

The sample was quickly held in a

perpendicular position every 30 seconds until a firm clot
had formed (87).

1:\)

~

Figure 10.

Use o .f 13- gauge trocar for subcutaneous implantation of the tumor.
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Tumor Dissection and Photography
The experimental and control animals were sacrificed,
using diethyl ether according to the Experimentation Schedule
shown in Table I.
After washing the dorsal skin with 70% ethanol, a
midline dorsal incision was made from the sacral area up to
the base of the neck (Figure 11).

The skin was retracted

slowly while it and the tumor were carefully dissected from
the underlying back musculature (Figure 12).

Both sides

of the dorsum were exposed equally for comparison regarding
local edema, vascular congestion and tumor appearance
(Figure 13).
of the tumor.

Photographs were taken prior to the removal
The tumor was then carefully dissected from

the supporting skin tissue (Figure 14) noting its adherence
or non-adherence, carefully weighed to the nearest 10

-4

g

using a Sartorius balance (type 2463, Fab. #161122) (Figure
15), and preserved in a 40% formaldehyde solution.
Histology
In the histology group, the tumor was removed with
the overlying skin for histological evaluation.

All speci-

mens were labeled with time of sacrifice, date, and origin
of specimen (control, experimental, histological group).
The specimens were th e n processed by embedding them in
paraffin.

After sectioning (7 microns thick), slides were

stained with hematoxylin/ e osin for microscopic study.
slides were prepared in the following manner:

The

Table I
Experimentation Schedule

Sacrifice time
(Implant = 0 hr)

(N = 27)

CONTROL

HEPARIN Na (N = 27)

+6 hrs

X

X

X

X*

X

X

X

X*

+12 hrs

X

X

X

X*

X

X

X

X*

+24 hrs

X

X

X

X*

X

X

X

X*

+2 days

XX

XX

XX

X*

XX

XX

XX

X*

+4 days

X

X

X

X*

X

X

X

X*

+8 days

X

X

X

X*

X

X

X

X*

*Experime ntal animal selected for histologica l evaluation .
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Figure 13.

Bilateral skin reflection for comparison.
in vascular congestion on the tumor side.

Note the increase
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a.

After sectioning, a specimen was positioned
on a slide and placed on a drying plate at
37°C for 24 hours, then

b.

Washed in 70% ethanol, then

c.

Placed in xylol 2 min to remove excess paraffin,
then

d.

Tranferred successively to 100%, 95%, 70%, 50%,
and 30% ethanol, 1 min each, then

e.

Stained in Harris' hematoxylin (diluted 1:9 with
distilled water) for at least 15 min, then

f.

Placed successively in 30% and 50% ethanol for
1 min each, then

g.

Destained in 70% acid alcohol until.s ectio ns
appear light red on gross inspection , then

h.

Washed momentarily in 70% ethanol to remove excess acid and placed in 70% alkaline alcohol
until sections became bluish in color, t hen

i.

Counterstained in 0.5% eosin in 95% ethanol
for 1 min, then

j.

Washed in 95% et hanol o nly until the excess
eos in was removed and th e sections appeared
purp l e in color, then

k.

Placed in absolute et hanol for not over 1 min
(prolonge d expos ure to e thanol will remove
all the eosin), then
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1.

Cleared in xylol (1 min o r longe r) and mounted
(thin medium no . 1 coverglass), and lastly

m.

When sufficiently harde ned, cleaned and
lab e led.

Animal Weight
All animals were weighed to the nearest g prior to
the implantation and at the time of sacrifice.
Stati s tical Evaluation
In many investigations the researche r is p rimarily
interested in discovering and evaluating diff e ren ces between
effects rather than documenting th e effects th emselves .

In

the comparison of the group means, the term treatme n t i s u sed
to ref er to th e basis on which the two groups were diff ere ntiat e d .

The goal of this statistical analysis (analysis

of variance) was to es tablish

whether o r not a n y difference

between the two tr e atments was significant (p < 0 . 05) .
A de fi nitive evaluation of the dat a was then conducted
utilizin g multi-variate

analysis.

RESULTS
Statistical Comparisons
Tables I I and III li s t the raw data obtained whi le
Table IV carries the mean data a nd co rrespo nding st andard
error of the me an.
A very hi ghly significant diff e ren ce in whole blood
clotting time was seen between the co ntrol and the experimental group (Table V) .

Th e average clotting time in th e

expe rimen ta l gr o up was prolonged in comparison to the aver age c l ot ting time in t h e control group (£

=

< 0 . 001) .

This

i llustrates the well known a n t i coagulan t action of heparin,
•

t h e only drug used in this st udy .
A ve r y hi ghly sign ificant difference (£

=

< 0 . 001) in

tumor we i gh t was also d etected between t h e two groups (Table
VI) .

This i s probably not due to d iffe r e n ces in i nocul u m

size, s ince inoculum s i ze was randomly distributed between
the experime n tal a nd co n trol gro up s.

There was no significant

difference in body weight chan ges between t h e control and
th e expe rime nt a l

gr o ups (Table VII).

In th e con tr ol g r o up there was a t r e nd toward inc r eas in g tumor s i ze with time but t hi s was no t statistical l y
signi fican t (Table VIII ) .

In t h e experi me n tal g r oup tumor

s i ze tend e d to level off after initial statistica l growth
34
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Table II
Raw Data for Untreated Group

No.

Time,
hrs

Tumor Weight,
mg

Clotting Time,
min

Body Weight
Change, g

1

6

06.5

2.3

-0.2

2

6

10 . 7

1.1

- 0.2

3

6

14 . 1

1.2

00 . 3

4

12

14.6

1.5

00 . 2

5

12

09.2

2. 7

00 . 0

6

12

06.8

2.1

00 . 0

7

24

06.2

1.3

00 . 0

8

24

17 . 8

1.0

00.1

9

24

14.3

1.5

00.0

10

48

04 . 4

1.9

00.0

11

48

05.5

2.0

00 . 2

12

48

09 . 7

1.8

00 . 0

13

48

09 . 0

1.6

00.2

14

48

10.3

1.7

00 . 0

15

48

08 . 2

2.0

00 . 0

16

96

09.4

1.5

00 . 2

17

96

20 . 7

2.0

00 . 0

18

96

11 . 5

1.8

-0.2

19

192

08 . 1

1.2

00 . 3

20

192

09 . 6

2. 1

00.2

21

192

09 . 8

1.2

00 . 4
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Table III
Raw Data f or Treated Gr oup

No .

Time,
hrs

Tumor Weight,
mg

Clotting Time,
min

Body Weight,
Change , g

22

6

07.5

4 .4

00.0

23

6

06 . 3

1.8

00 . 0

24

6

05.2

4 .4

00 . 0

25

12

02.8

17. 6

00 . 0

26

12

05 . 1

2. 6

00 . 0

27

12

01.7

8.0

00 . 0

28

24

05.2

2. 9

-0.2

29

24

05.8

4.3

-0. 2

30

24

02 . 7

3.4

00 . 3

31

48

02.1

3. 3

00.4

32

06.3

3. 6

00 . 3

33

48
. 48

05 . 3

2. 7

00 . 4

34

48

06 . 0

3. 2

-2 . 0

35

48

05 . 3

3.0

- 0.4

36

48

04.8

2.9

00 . 2

37

96

04.6

3. 5

00 . 3

38

96

04 . 9

4.2

-0. 4

39

96

05.8

5. 2

- 0.4

40

192

03 . 7

3.1

00 . 4

41

192

05 . 7

5.1

00 . 5

42

192

06 . 3

1.1

00 . 4

Table IV
Mean Values + 1 Standard Error of the Mean

Time in Hours
24

Term

6

12

Tumor

T

6.330 + 0.664

3. 200 + 1.002

-

Weight, g

u

10.430 + 2.170

10.190 + 2.186

Clotting

T

3.5

+ 0.9

9.4

+ l. 7

3.5

-

+ 0.4

3.1

-+ 0.1

4.3

+ 0.5

3.1

-

Time, min

u

1.5

+ 0.4

2.1

+ 0.3

1.3

±. 0.1

1.8

+ 0.1

1.8

-+ 0.1

1.5

+ 0.2

Weight

T

0.0

+ 0.0

0.0

+ 0.0

-0 . 3

+ 0.0

-1.8

+ 0.4

-1.7

+ 0.2

4.3

+ 0.0

Change, g

u

-0.3

+ 0 .2

0. 7

+ 0.1

0.3

+ 0 .0

0.7

+ 0.0

0.0

+ 0.1

3.0

+ 0.1

T

48

96

4.560 + 0.949

4.960 -+ 0.614

5.100 + 0.255

5.230 -+ 0.786

12.760 + 3.435

7.850 + 0.971

13.860 + 2.454

9 . 160 + 0.537

-

192

= treated group

U = untreated group
a

Means represent data for three animals, except for the +48 hour values which represent six animals per.

+ 1.2

w

.....:)

Table V
Analysis of Variance Test Regarding
Clotting Time

df

Sum of
Squares

Mean Square

Between
treatments

1

71.501

71.501

Between
time

5

55.095

11.019

Residual

35

174.003

Total

41

300 .599

Term

df
~

= Degrees

of freedom

= Observed level of significance

s

2

= 4.449

F . 0.05
cr1t .

p

16.073

4.12

<0.001

2.477

2.48

0.05

F

obs.

w

00

Table· VI
Analysis of Variance Test Regarding
Tumor Weight

Term

Between
treatments

df

Sum of
Squares

1

305.640

305.64

F

obs .

33.30

F

. 0.05
cr1t.

E.

4 . 12

<0.001
w

Between
times·

5

Residual

35

321.22

Total

41

681.508

10.92

54.649

df = Degrees of freedom

£

Mean Square

= Observed level of significance

s

2

= 9 . 178

1.19

2 . 48

>0. 10

t0

Table VII
Analysis of Variance Test Regarding
Body Weight Change

Term

df

Sum of
Squares

Mean Square

F

obs.

F

.

cn. t.

0 . 05

.E.

Between
treatment

l

0.086

0 . 086

0.55

4.12

>0.20

Between
times

5

0.868

0 . 174

1.12

2.48

>0.20

Residual

35

5.447

Total

41

6 . 401

df

fl:>.

0

= Degrees of freedom

.E. = Observed level of significance

s

2

= 0.156
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Table VIII
Analysis of Variance Within the Untreated
Group in Regard to Tumor tveight

Variable

F

F . 0.05
cr1t .

Time

1.236

<

2 . 90

>0,3

Clotting

0 .605

<

3 .28

>0 . 8

Weight

0 . 702

<

2.90

>0 . 6

obs .
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(incr ease in tumor mass).

This again, however, was not a

significant difference (Table IX).
and body

weigh~

Also clotting times

changes within each group remained statis-

tically u n chan ged .
The results were subjected to multiple-variate
a nalysis (ANOVA).

From Table X it is obvious that treat-

ment has affected tumor growth significantly (£ = < 0.0001).
Time has no signi ficant effect on tumor weight .

There is

no significant interaction between treatment and time with
reference to tumor weight .

Therefore, it is apparent that

tumor weight differences are attributable to treatment and
not to time.
Table XI demonstrates clotting times are significantly
affected by treatment.

The treatment group has much longer

clotting times than the control group .

Duration of t r eat-

ment has an effect atE= 0 . 06 but has no effect atE= 0.05 .
In other words, at E = 0.05 (the traditional probability
l evel for biological research) there i s no significant interaction between tr eatment and duration of treatment with reference to their effect on clotting time; a large number of
test subjects would probably produce significant interaction.
Table XII demonstrat es no significant difference in
body weight changes .

Neither treatment nor time has any sig-

nificant effect on changes in body weight of the animals .

It

is probable that if this study has been contained for a longer
period, duration of treatment may significantly affect change
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Table IX
Analysis of Variance Within the
Treated Group in Regard to Tumor Weight

Variable

F

Time

1.571

<

2.90

>0.2

Clotting

1. 745

<

19.43

>0 . 4

Weight

0.222

<

2.84

>1.0

Fcr i t . 0.05

obs.

Table X
ANOVA Multivariate Analysis of the Interaction between Tumor Weight as the Dependent Variable
with Treatment and Time as the Independent Variables

Source of
Variation

Sum of
Squares

df

Main effects

360.289

6

60.238

6.827

2 . 42

<0 . 000

Treatment

305.640

1

305.640

34.751

4.17

<0.000

54.649

5

10.930

1.243

2.53

0.314

57.364

5

11.473

1 . 304

2 . 53

0.288

Explained

417.653

11

37.968

4.317

2 .10

0 . 001

Residual

263.855

30

8.795

Total

681.508

41

16.622

Time
Two-way
interaction

Mean Square

F
obs .

F . 0.05
cr1t.

E.

H::>
H::>

Table XI
ANOVA Multivariate Analysis of the I nteraction bet ween Cl otting Time as the Dependent Variable
with Trea t ment and Time as the Independent Variables

Source of
Variation

Sum of
Squares

df

Main effects

126 . 596

6

21.099

4 . 743

2.42

0.002

Treatment

71.501

1

71.501

16 . 073

4.17

0.000

Time

55.095

5

11.091

2 . 477

2.53

0.054

Mean Square

F

obs.

F

crit .

0.05

.E.

~

Two way
interaction

(.n

40.548

5

8.110

1 . 823

2 . 53

0. 138

Explained

167.144

11

15 . 195

3 . 416

2.10

0.004

Residual

133.455

30

4.449

Total

300.599

41

7.332

Table XII
ANOVA Multivariate Analysis of the Interaction between Body Weight Change as the Dependent
Variable, Treatment, and Time as the Independent Variables

Source of
Variation

Sum of
Squares

Main effects

0.955

6

0.159

0.907

2.42

0.503

Treatment

0.086

1

0.086

0.490

4.17

0 . 480

Time

0.869

5

0.174

0.991

2.53

0.440

df

Mean Square

F
obs.

F . 0 . 05
cr1t.

E.

~
Q")

Two-way
interaction

0 . 185

5

0.037

0 . 211

2.53

0 . 955

Explained

1.140

11

0.104

0 . 591

2.10

0.821

Residual

5 . 262

30

0.175

Total

6.401

41

0.156
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in body weights.
Macroscopic Comparison s
On gross observation, there was no difference
between the control a nd the exper imental g roup with reference
to color, texture and general appearance of the implanted
tumor at sacrifice.

However, surrounding vascular conges-

tion as evidenced by local vasodilation and local edema appeared to be more pronounced in the control group (see
Figures 16 - 19).

Also an overlying ski n attachment ap-

peared to be more freq uent in the con trol group.
Table XIII summarizes the observed incidence of
vasodilation a nd local edema--parameters which did not
lend -the mselves to precise measurement.

As the tumors were

b e ing removed, both sides of the skin were exposed .

Each

animal during dissection was graded a plus or a minus according to t h e degree of vasodilation .

During tumor dis-

section, local edema was also graded in a subjective manner.

In addition,no a reas of hemorrhage were seen .

Microscopic Comparisons
Tumor sections from the two groups were evaluated
microscopically for the numb e r of viable cells .

Th e r e ap-

peare d to be a g r eater number of viable cells in th e control
group (Figures 20, 22 , 24, 26, 28, 30) .

In the expe rime ntal

group, viable cells were limited to the zo nal area at the
surface of the t umor (s ee Figures 21, 23, 25, 27, 29, 31).

~

00

Figure 16 .

Demonstrating vasodilation in control animals (Day +2). Note the
presence of local edema and vesse~ congestion in the control
animal .

~
(!)

Figure 17.

De monstrating vasodilation in experimental animal (Day +2) .
In the
experimental animal cutaneous vessels near the tumor do not show
engorgement.

CJl

0

Figure 18 .

Demonstrating vasodilation in control animals (Day +4).
gestion of overlying skin vessels is observed .

Obvious con-

c.n
f-'

Figure 19.

Demonstrating reduced vasodilation in experimental animals (Day +4).
Note size of vessels in vicinity of tumor as compared to those in
Figure 17.
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Table XIII
Quantal Incidence of Rated Factors
Time in Hours

Vasodilation

Local Edema

6

12

24

48

96

192

T

0/3

0/3

1/3

0/6

0/3

3/3

u

0/3

1/3

2/3

3/6

3/3

3/3

T

0/3

0/3

·1/3

2/6

2/3

3/3

u

0/3

1/3

3/3

3/6

3/3

3/3

(J1

w

Figure 20 .

Mouse mammary tumor in control group at 6 hours (25 X).
hours necrotic and viable tumor cells are observed .

At 6

(,}1

~

Figure 21.

Mouse mammary tumor in experimental group at 6 hours (25 X) .
necrosis is evident throughout the implant.

Much

(}1

CJl

I.

Figure 22.

Mouse mammary tumor in control group at 12 hours (25 X).
In contrast
to Figure 20, an area of central necrosis is observed. Tumor is more
cellular and necrosis less evident.

(J1
(j')

Figure 23.

Mouse mammary tumor in experimental group at 12 hours (25 X). Central
necrosis with viable tumor cells seen only at the periphery. Note also tha t
PMNs and macrophages appear
at the tumor's periphery.

(}1

~

Figure 24.

Mouse mammary tumor in control group at 24 hours (25 X). Again note a
mass of neoplastic cells with fewer inflammatory elements and a lack
of a central necrotic region.

CJ1
00

Figure 25.

Mouse mammary tumor in experimental group at 24 hours (25 X).
tral necrotic area can be observed.

A cen-

(Jl
\!)

Figure 26.

Mouse mammary tumor in control group at 48 hours (25 X) . This section
is similar in appearance to Figure 20 and Figure 22 . Tumor lacks a
central necrotic area.

(j')

0

Figure 27 .

Mouse mammary tumor in experimental group at 48 hours (25 X). A large
area of necrosis with very few viable . tumor cells can be observed.

0)

}-J.

Figure 28.

Mouse mammary tumor in control at 96 hours (40 X).
At higher magnification, nests of growing tumor cells can be observed .

(j)

N

Figure 29.

Mouse mammary tumor in experimental group at 96 hours (25 X) .
tumor cells are observed only at the periphery of the tumor .

Viable

0')

0.::

Figure 30.

Mouse mammary tumor in control group at 192 hours (40 X).

Solid

tumor lobules separated by connective tissue with neo-vasculature.

())
~

Figure 31.

Mouse mammary tumor in experimental group at 192 hours (40 X).

A large

area of n ecrosis with relatively low numbers of tumor cells located a long
the edge of the tumor.
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Definite necrosis was seen in most of the histologic sections
prepared from experimental animals.

However, in a few slides

viable cells were seen centrally and these were thought
to be the result of the sectioning process (see Figures 23,
31).

Leukocyte infiltration (polymorphonuclears, microphage, lymphocytes) was observed, and a great deal of intragroup variability was seen (see Figures 20-31).

DISCUSSION
This experiment was designed to demonstrate any
effects that heparin might have on the growth of implanted
mammary tumors in a susceptible, genetically uniform breed
of mice.
It is clear from the data collected here that
heparin treatment affects tumor growth as early as 6 hours
after tumor implantation.

This inhibitory effect became

progressively more apparent until the time of sacrifice.
This favorable r espo ns e is probably related to heparin's
antithrombin activity.

The premise could be substantiated

by designing a study in which heparin is replaced by an
a nti coagulant agent with a differe nt mechanism of action
such as coumarin.

Coumarin primarily affects the synthesis

of Vitamin K-dependent clotting factors (s erum beta globu1 ins).
Th e dose of heparin us e d in this expe riment, twice
the normal dose, clearly prolonged the clotting time, a
necessary consequence of its inhibitory action o n thrombin
formation.

Since the presence of thrombin favo rs the forma-

tion of a stab l e "fibrin cocoon" f o r the tumor ( 49), hepari n
theoretically should be able to preve nt the formation of
this presuma bly protective barrier.
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Dvorak has hypothesized that a relationship exists
between tumor growth and fibrin cocoon formation (49).

If

this is true, then chemically interfering with the synthesis
of such a structure should result in an altered tumor growth.
From this investigation, it is apparent that such a relationship exists although the precise nature of this relationship
is not clear.

However, the presence or the absence of

fibrin was not demonstrated in the present study.
Although weight differences between the tumors of
the two groups was the primary focus of this research, less
objective criteria such as degree of inflammation, overlying skin adhesion (attachment) and host immune response
were also evaluated.

For these parameters, differences

between the two groups were not large enough to be sig•

nificant.

Of interest was the fact that, in the experi-

mental group viable tumor cells were limited to the zonal
area at the surface of the tumor.

This can perhaps be ex-

plained by the fact that oxygen and nutrients can diffuse
into this zone to keep the tumor cells alive.
In 1972, Elias and Bruganolas

reported the bene-

ficial effect of anticoagulation in four patients with metastatic carcinoma of the lung not responding to the multiple
chemotherapeutic agents alone.

After the addition of heparin,

excellent clinical responses were seen and confirmed (65).
In 1975, Elias, Shukla, and Mink again reported a favorable
experience using heparin in patients with metastatic

68
carcinoma of the lung (63).

Fourteen patients not re-

sponding to multiple conventional chemotherapy andjor radiotherapy showed significant responses to the same chemotherapeutic agent andjor radiotherapy after heparinization
(52, 63).
However, Rohwedder and Sagastume (64) have reported
no significant beneficial effect after the addition of heparin to anti-cancer therapy in patients with metastatic
carcinoma of the lung.
All of the studies cited above tested heparin in
solid tumors .

In 1978, Drapkin et al. reported on nine

patients with acute promyelocytic leukemia who showed favorable responses to heparin therapy (88).
Zacharski et al.

More recently,

(60) reported on 25 patients with small

cell carcinoma of the lung receiving warfarin in addition
to conventional cancer therapy.

Median survival in the

treatment group was twice as long as in the control or nonanticoagulated group.
The majority of the clinical studies cited above
support the hypothesis of this research project that anti coagulants can inhibit tumor growth by inhibiting thrombin
formation .

=

SUMMARY
Fifty-four of the inbred strain

c 3 HjHeJ

Jackson

Laboratory female mice approximately one year old and
weighing 20- 26 grams were implanted with spontaneously
occurring mouse mammary tumors and equally divided into
control and experimental groups.

Th e experimental group

received 4.0 mgjkg sodium heparin (128 Ujmg) intraperitoneally on a twelve-hour schedule .

Effective anticoagula-

tion was demonstrated by a prolongation of clotting time .
Animals (C HjHeJ mice) were sacrificed at varying inter3
vals up to 8 days, tumors retrieved and weighed .

Definite

retardation of tumor growth was demonstrated in the experimental group.
The following conclusions appear justifie d:
(i)

Heparin at th e dosage and route used her e
is an effective anticoagulant agent .

(ii)

No major hemorrhagic accidents were see n
in the anticoagulated mice at th e dos e
used.

(iii)

Implant e d mous e mammary tumor growth was
inhibite d by heparin .

(iv)

Polymorphonuclear, macrophage , T lympho cy t e
and tumor cell necrosis appeared to b e too
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variable for specific conclusions to be
drawn.
(v)

Overlying skin attachment (adhesion), blood
vessel congestion (dilation) and the presence
of local edema appeared more pronounced and
occurred more frequently in the control
group.

The author agrees with Zacharski (60) that anticoagulant therapy may have an important role to play in the
treatment of solid tumors such as mouse mammary adenocarcinoma.

Further investigation will be necessary to con-

firm these findings and to confirm that the beneficial effect of heparin is exclusively due to its antithrombin
activity.

Experiments utilizing a pharmacologically dif-

ferent anticoagulant (e.g. warfarin) would be especially
meaningful .
The present study limited heparin treatment t o a
maximum term of 8 days.

It would be useful to study

the effect of heparin for much longer periods.

End points

for such long term experiments could be animal death o r
the complete disappearance of th e implanted tumor mass.
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